Focus Rheums| Dr. Jekyll or Mr. Hyde? (video)

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis

  |  Issue: September 2018  |  

In both groups, adverse events were similar, with mostly mild and moderate reactions being reported. One filgotinib-treated patient developed pneumonia with a fatal outcome; another filgotinib-treated patient developed herpes zoster. No cases of opportunistic infections, tuberculosis, thromboembolism or malignancy were observed. Additionally, no new laboratory changes were noted during this trial compared with prior filgotinib clinical trials in patients with rheumatoid arthritis.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Pfizer Inc. News release: Pfizer and Lilly announce positive top-line results from Phase 3 trial of tanezumab for the treatment of osteoarthritis (OA) pain. 2018 Jul 18.
  2. Pfizer Inc. News release: Pfizer and Lilly receive FDA fast track designation for tanezumab. 2018 Jun13.
  3. Gilead Sciences Inc. News release: Gilead and Galapagos announce results with filgotinib in the phase 2 EQUATOR study in psoriatic arthritis and progression into phase 3 for the SELECTION study in ulcerative colitis. 2018 May 30.

Related Articles

    U.S. & E.U. Differ on Filgotinib for RA

    This summer, the FDA rejected a new drug application for filgotinib to treat RA in the U.S., but a European Medicines Agency committee issued a positive opinion, moving filgotinib closer to authorized use in the E.U.